Moatable, Inc.

OTCPK:MTBL.Y Stock Report

Market Cap: US$5.9m

Moatable Past Earnings Performance

Past criteria checks 0/6

Moatable has been growing earnings at an average annual rate of 36.2%, while the Software industry saw earnings growing at 21.7% annually. Revenues have been growing at an average rate of 27.2% per year.

Key information

36.19%

Earnings growth rate

34.94%

EPS growth rate

Software Industry Growth17.33%
Revenue growth rate27.20%
Return on equity-6.90%
Net Margin-1.77%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Analysis Article • Sep 14

We're Keeping An Eye On Moatable's (NYSE:MTBL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 02

Here's Why We're Not Too Worried About Renren's (NYSE:RENN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Dec 19

Best Idea: Renren And Beyond

Summary Three things I look for when looking at companies. 2022: It was all about Renren. 2023: What ideas are out there? YCharts Best Ideas Each year, I highlight one top position as a best idea for the subsequent year. This year, the idea has been Renren (RENN), one of my top three holdings. How do I pick? I look for three things: Something safe, lucrative, and uncorrelated with the overall markets. Bottoms up! I look for ways to make money in any market – up, down or sideways. Macro prognosticators are far greater in quantity than quality. What I don’t do: Macro I stay out of the whole discussion of which way the stock market will go. I have no idea. I doubt many of the people who make bold macro calls get it right a statistically significant percentage of the time. What I do: Events Instead I focus on discreet corporate events that unlock shareholder value and do detailed firm-level analysis to find and exploit them to make money in any market. What kind of events? Mostly litigation, M&A, and in particular merger securities (which overlaps quite a bit with litigation). What are we really doing here? Counterparty selection. Avoiding being the patsy. Narrowing down who you’re competing against due to narrow mandates and complexity. Renren My best idea for 2022 was Renren. The year is not yet out but with the S&P 500 down 18%, RENN is up over 120% year to date. It started the year under $15. It will end the year with a $31.62 cash distribution. This was the result of a complex litigation that I was intimately involved with for a long time. It was safe, lucrative, and had absolutely nothing whatsoever to do with what the overall stock market did - it just happened to be publicly traded. When first presented, I estimated the probability of its upside scenario at 90%, now that's 100%. Excluding the cash distribution, I estimated that equity stub would be worth at least $1 and maybe as much as $4. Today, it costs under $1. It's exactly what I look for when sizing a top position and picking an annual idea. Spectrum As I approach the decision on what to name my best idea for 2023, I’m looking for another case that will be safe, lucrative, and uncorrelated with the stock market. One candidate is Spectrum Brands (SPB). It finished this past quarter under $40 per share, has recovered a bit but still trades for under $60 and is worth over $80. The kicker, as with Renren, is litigation. The US Department of Justice sued to block a transformative asset sale that would pay SPB in cash more than their entire market cap. It's a great deal but the current administration is quite wary of deals and claims this would be monopolistic. My view is that the case is weak, especially after the companies named a strong buyer for the entire overlapping product lines. The deal will probably get done by the middle of next year, which could catapult SPB shares regardless of what the rest of the market is doing. Antitrust I blurted out two edgy, actionable ideas – a favorite recent one and upcoming one. But now let me back up to discuss M&A heading into 2023 more generally. This category is a great solution for capital if you don’t know what the market is going to do next. But the solution has a few problems worth highlighting. First the aforementioned antitrust agencies: They're particularly hostile at the moment and will bring a lot of suits to block deals, especially customer-facing deals in tech or healthcare. I like cases such as SPB that are already in front of a judge. The FTC and DoJ can bring cases, but they have to make their case. I prefer to avoid getting hit with the stock price reaction to such suits and then load up when the government brings dumb ones likely to lose. Financing A second problem: The credit market for deal financing is quite weak. If buyers need to raise a lot of debt from banks for their deals, those deals are not likely to get done. While antitrust has been making life hard for strategic deals, the credit market has been making life particularly hard for private equity’s leveraged buyouts. In fact one of the best places in the market for short ideas in 2022 has been in speculated takeover candidates. Many of these made it into the press without making it to definitive merger agreements. So I like M&A but I'm wary of both antitrust risk and financing risk – what kind of deal does that leave me? Looking back at 2022, that left me Twitter, my biggest and best risk arbitrage position ever. Activision Looking forward, here are some of the opportunities. Microsoft (MSFT) is buying Activision (ATVI) in a deal that the FTC is trying to block on dubious antitrust grounds. They can delay it and even interfere enough to stop it, especially if they get an assist from foreign regulators such as the UK’s CMA. But the deal price is $95, as of this writing the shares cost about $77 and they aren’t worth all that much less than they cost even without the deal. So this was not worth it before the antitrust problems were fully priced in but is increasingly interesting since then. This may be one of the best definitive merger arbs at the moment, so is another I have my eye on. Amplify In terms of deal financing, eventually the credit market will stabilize. It doesn’t even need to strengthen as much as just settle down so participants know where to price debt. That’s why I’m focusing on situations for 2023 that need a few more months anyways. One in particular is Amplify Energy (AMPY). It costs about $7 per share and is worth at least twice that. The value is likely to be unlocked well before the end of next year. First, they have a damaged pipeline that needs fixing. Then, they have commodity hedges that can be rolled off. They will be able to use the repaired pipe for the cash flow necessary to completely deleverage their balance sheet. At which point, this wildly undervalued and undersized oil and gas company will be a layup of a sale candidate to a larger strategic buyer. This is safe, lucrative, uncorrelated, and likely to be a one-decision investment from here. If you can buy any under $10 per share, you will probably get a significant premium to that price in a sale. Ideally, the timing could work out so that it closes late enough in 2023 to get long-term tax treatment on what could be a monster gain. This is my biggest and favorite position at the moment (a best idea candidate, but it's volatile, so no decision until closer to Year End so I can see the starting price). Abiomed This one will actually be over (in terms of the window for taking advantage of it) by month end. It's a merger security that avoids any antitrust or financing risk. You could lose a little over a dollar (depending on the specific price you get) or make over $33. Johnson & Johnson (JNJ) is buying Abiomed (ABMD). It has already secured all regulatory approvals including the US, Germany, Austria, and Japan. Then by the end of this week they will tender for shares and send you $380 in cash per share, returning approximately your entire cost basis. That leaves you with, at worst, a tie. Then what? Then you get a non-tradable contingent value right worth up to $35. Sometimes these pay out, sometimes they don’t, and often they settle years later when holders sue the issuers over their treatment. You’re paying just over a dollar (I paid less than nothing) for a ticket that could settle or payout many times that. Details from the offer:
Seeking Alpha • Nov 10

Renren Non-GAAP EPS of $2.77, revenue of $21.3M

Renren press release (NYSE:RENN): 1H Non-GAAP EPS of $2.77. Revenue of $21.3M (+42.0% Y/Y).
Seeking Alpha • Apr 28

Renren: Our Best Long For 2022

How has RENN done so far? What is it worth? What happens next?
Seeking Alpha • Jan 19

Renren: An Update On Our Best Idea For 2022

Sifting the World presented our best idea to members last month. A lot has happened since then in the market and this stock. Here is why it is a huge opportunity today at under $25.
Seeking Alpha • Jan 10

Renren Is So Bad It's Good

StW’s best idea for 2022. A disastrous – but appealable – decision. An uncorrelated opportunity for the New Year.
Seeking Alpha • Oct 18

Renren In Search Of Identity As Its Stock Surges On Lawsuit Settlement

A 45% surge in shares of Renren, once pegged as the ‘Facebook of China,’ earlier this month was fueled by settlement of a shareholder lawsuit. Despite a $600 million market value after the jump, company is still in search of a long-term business model. In trying to stay alive and thrive during the years when its networking platform was in decline, Chairman Chen Yizhou steered Renren in a new direction by buying stakes in startups that had little to do with the social media.
Analysis Article • Feb 15

What Type Of Shareholders Make Up Renren Inc.'s (NYSE:RENN) Share Registry?

If you want to know who really controls Renren Inc. ( NYSE:RENN ), then you'll have to look at the makeup of its share...

Revenue & Expenses Breakdown

How Moatable makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:MTBL.Y Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2575-13523
30 Jun 257113421
31 Mar 256703420
31 Dec 2463-23219
30 Sep 2460-33418
30 Jun 2456-113217
31 Mar 2454-193218
31 Dec 2352-103318
30 Sep 2351-293318
30 Jun 2350-753418
31 Mar 2348-683417
31 Dec 2246-773516
30 Sep 2242-1093615
30 Jun 2239-613714
31 Mar 2235-833612
31 Dec 2132-1033411
30 Sep 21-4-46268
30 Jun 2125-49299
31 Mar 2122-31309
31 Dec 2018-143210
30 Jun 20176-1356920
31 Mar 20260-317122
31 Dec 1915182222
30 Sep 19389-726124
30 Jun 19450-447427
31 Mar 19475-1429127
31 Dec 1867-625922
30 Sep 18490-15411628
30 Jun 18437-17411027
31 Mar 18288-118118
31 Dec 1717597217
30 Sep 17124-1207920
30 Jun 1781-1496919
31 Mar 1774-1786819
31 Dec 1647-63538
30 Sep 1646-1447316
30 Jun 1648-2027520
31 Mar 1644-2287924
31 Dec 1541-2228227
30 Sep 1515-1347720
30 Jun 1563-839134

Quality Earnings: MTBL.Y is currently unprofitable.

Growing Profit Margin: MTBL.Y is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MTBL.Y is unprofitable, but has reduced losses over the past 5 years at a rate of 36.2% per year.

Accelerating Growth: Unable to compare MTBL.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTBL.Y is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (14.3%).

Return on Equity

High ROE: MTBL.Y has a negative Return on Equity (-6.9%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 13:41
End of Day Share Price 2026/05/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moatable, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alicia YapBarclays
Eddie LeungBofA Global Research
Muzhi LiCitigroup Inc